title: HPV Infection in Cervical and Other Cancers in Saudi Arabia: Implication for Prevention and Vaccination.
abstract: Human papillomavirus (HPV) is closely associated with cervical cancer that the incidence of this tumor is regarded as a surrogate marker for HPV infection in countries lacking epidemiological studies. HPV is also implicated in subsets of anogenital and oropharyngeal cancers. Although cervical cancer is the third most common cancer in women worldwide, its reported incidence is low in Saudi Arabia, ranking number 12 between all cancers in females and accounts only for 2.4% of all new cases, despite the lack of national screening programs. However, the limited available studies from Saudi Arabia indicate that HPV prevalence and genotypes' distribution in invasive cervical cancer show similar pattern as in the world. Cytology screening (Pap smear) and HPV vaccinations are the two preventive measures against cervical cancer. The two available vaccines are effective against the two most common HPV genotypes (HPV-16 and -18). Since 92% of cervical tumors in the Kingdom are infected with HPV of which 78% are HPV-16 and -18 genotypes, vaccination is expected to protect against more than two-third of cervical cancers in Saudi Arabia. Nevertheless, due to its low incidence (2.1/100,000 women), a proper cost-effectiveness analysis is required to justify the implementation of a costly vaccine bearing in mind that HPV could potentially be associated with about 3% of all cancers. However, further studies are needed to ascertain the real prevalence of HPV at the population level at large, its association with various types of cancers, and also the impact of local tradition and emerging behavioral trends that could affect HPV transmission and consequently the effectiveness of applying national vaccination program.
authors.affiliation: Research Centre, King Faisal Specialist Hospital and Research Centre , Riyadh , Saudi Arabia.
authors.forename: Ghazi
authors.initials: G
authors.lastname: Alsbeih
keywords: HPV genotype; HPV-16; Saudi Arabia; cervical cancer; human papillomavirus
references.citation: Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):467-75
references.pmid: 15734974
references.citation: Lancet Oncol. 2008 May;9(5):425-34
references.pmid: 18407790
references.citation: Saudi Med J. 2003 Nov;24(11):1225-9
references.pmid: 14647558
references.citation: Saudi Med J. 2006 Oct;27(10):1498-502
references.pmid: 17013471
references.citation: Vaccine. 2008 Nov 18;26(49):6258-65
references.pmid: 18835313
references.citation: Ann Saudi Med. 2001 Jan-Mar;21(1-2):92-6
references.pmid: 17264603
references.citation: Gynecol Oncol. 2010 Jul;118(1):29-34
references.pmid: 20406711
references.citation: J Natl Cancer Inst. 2009 Jun 3;101(11):782-92
references.pmid: 19470949
references.citation: Ann Saudi Med. 2007 Jul-Aug;27(4):268-72
references.pmid: 17684431
references.citation: J Infect Dis. 2010 Dec 15;202(12):1789-99
references.pmid: 21067372
references.citation: Int J Gynecol Cancer. 2011 Jul;21(5):907-10
references.pmid: 21697680
references.citation: Clin Microbiol Infect. 2010 Mar;16(3):262-6
references.pmid: 19438642
references.citation: J Clin Virol. 2005 Mar;32 Suppl 1:S16-24
references.pmid: 15753008
references.citation: Saudi Med J. 2009 May;30(5):633-7
references.pmid: 19417961
references.citation: Gynecol Oncol. 2011 Jun 1;121(3):522-6
references.pmid: 21353296
references.citation: Br J Ophthalmol. 1997 Jul;81(7):595-8
references.pmid: 9290377
references.citation: J Pak Med Assoc. 1999 Jul;49(7):157-61
references.pmid: 10599201
references.citation: Lancet Oncol. 2008 May;9(5):404-6
references.pmid: 18452848
references.citation: J Natl Cancer Inst. 2009 Apr 1;101(7):475-87
references.pmid: 19318628
references.citation: Hum Gene Ther. 2012 Dec;23(12):1301-12
references.pmid: 22971245
references.citation: Ann Saudi Med. 2000 Sep-Nov;20(5-6):355-7
references.pmid: 17264620
references.citation: Br J Cancer. 2010 May 25;102(11):1657-60
references.pmid: 20407442
references.citation: Ann Saudi Med. 2003 May-Jul;23(3-4):229-30
references.pmid: 16985334
references.citation: Saudi Med J. 2011 Nov;32(11):1155-60
references.pmid: 22057604
references.citation: Lancet Oncol. 2010 Nov;11(11):1048-56
references.pmid: 20952254
references.citation: Ann Saudi Med. 2007 Jan-Feb;27(1):1-5
references.pmid: 17277496
references.citation: Expert Rev Vaccines. 2009 Dec;8(12):1663-79
references.pmid: 19943762
references.citation: Ann Saudi Med. 2013 Jan-Feb;33(1):13-7
references.pmid: 23458934
references.citation: Lancet Oncol. 2010 Aug;11(8):781-9
references.pmid: 20451455
references.citation: Oncologist. 2005 Aug;10(7):528-38
references.pmid: 16079320
references.citation: Saudi Med J. 2007 Dec;28(12):1810-8
references.pmid: 18060207
references.citation: J Med Virol. 2012 Jun;84(6):947-56
references.pmid: 22499018
references.citation: Lancet Oncol. 2005 Apr;6(4):204
references.pmid: 15830458
references.citation: Lancet. 1995 Mar 11;345(8950):650
references.pmid: 7898199
references.citation: Prev Med. 2011 Oct;53 Suppl 1:S12-21
references.pmid: 21962466
references.citation: Discov Med. 2010 Jul;10(50):7-17
references.pmid: 20670593
references.citation: JAMA. 1994 Jun 15;271(23):1866-9
references.pmid: 8196145
references.citation: Lancet. 1999 Mar 13;353(9156):856-7
references.pmid: 10093972
references.citation: Vaccine. 2012 Jun 6;30(26):3867-75
references.pmid: 22516212
references.citation: J Pathol. 1999 Sep;189(1):12-9
references.pmid: 10451482